Intuitive Surgical
ISRG
414.52
+9.76
+2.41%
Intuitive Surgical
US · ISRG
#157 by market cap
Listed 1970
414.52
+9.76
+2.41%
Live - 5344 symbols - heartbeat 6s ago
· 2026-10-08 08:25
Pre-market
413.00
-0.37%
After-hours
414.55
+0.01%
Overnight
412.78
-0.42%
- Market cap
- 146.44B
- P/E (TTM)i
- 47.54
- P/Bi
- 8.06
- EPSi
- 7.87
- Div yieldi
- 0.00%
- 52W posi
- 31%
Reader sentiment
Are you bullish or bearish on ISRG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 36.81, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +20.51% YoY
Margins
- Gross margin
- 66.00%
- Operating margin
- 29.27%
- Net margin
- 28.38%
Key ratios & quality
- PEG ratioi
- 1.62
- Altman Z-Scorei
- 36.81
PEG uses trailing P/E against the 3-year net income growth rate (29.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.72B | 4.48B | 4.36B | 5.71B | 6.22B | 7.12B | 8.35B | 10.06B |
| Gross profit | 2.60B | 3.11B | 2.86B | 3.96B | 4.20B | 4.73B | 5.63B | 6.64B |
| Selling & admin expenses | 986.60M | 1.18B | 1.22B | 1.47B | 1.74B | 1.96B | 2.14B | 2.39B |
| Research & development | 418.10M | 557.30M | 595.10M | 671.00M | 879.00M | 998.80M | 1.15B | 1.31B |
| Operating profit | 1.20B | 1.37B | 1.05B | 1.82B | 1.58B | 1.77B | 2.35B | 2.95B |
| Pretax profit | 1.28B | 1.50B | 1.21B | 1.89B | 1.61B | 1.96B | 2.67B | 3.31B |
| Tax | 154.50M | 120.40M | 140.20M | 162.20M | 262.40M | 141.60M | 336.30M | 434.80M |
| Net profit | 1.13B | 1.38B | 1.07B | 1.73B | 1.34B | 1.82B | 2.34B | 2.88B |
| Basic EPS | 3 | 4 | 3 | 5 | 4 | 5 | 7 | 8 |
| Diluted EPS | 3.16 | 3.85 | 2.94 | 4.66 | 3.65 | 5.03 | 6.42 | 7.87 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.25B | 2.44B | 2.51B | 2.87B | 2.77B | 2.89B |
| Gross profit | 1.46B | 1.62B | 1.66B | 1.90B | 1.83B | 1.96B |
| Selling & admin expenses | 563.40M | 561.20M | 573.30M | 687.10M | 613.30M | 617.90M |
| Research & development | 316.20M | 313.30M | 329.40M | 352.90M | 361.90M | 370.60M |
| Operating profit | 578.10M | 743.40M | 759.70M | 864.30M | 855.30M | 971.90M |
| Pretax profit | 668.50M | 832.10M | 855.20M | 955.60M | 940.40M | 1.05B |
| Tax | -35.20M | 167.90M | 146.00M | 156.10M | 114.40M | 231.40M |
| Net profit | 703.70M | 664.20M | 709.20M | 799.50M | 826.00M | 823.20M |
| Basic EPS | 2 | 2 | 2 | 2 | 2 | 2 |
| Diluted EPS | 1.92 | 1.81 | 1.95 | 2.21 | 2.28 | 2.29 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.33B | 4.66B | 6.63B | 5.84B | 6.25B | 7.89B | 7.11B | 9.78B |
| Cash & ST investments | 3.06B | 3.22B | 5.17B | 4.23B | 4.12B | 5.22B | 4.01B | 5.93B |
| Inventory | 409.00M | 595.50M | 601.50M | 587.10M | 893.20M | 1.22B | 1.49B | 1.84B |
| Total assets | 7.85B | 9.73B | 11.17B | 13.56B | 12.97B | 15.44B | 18.74B | 20.46B |
| Total current liabilities | 820.60M | 1.03B | 965.20M | 1.15B | 1.42B | 1.66B | 1.75B | 2.01B |
| Short-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,159,200,000.00 | 1,448,500,000.00 | 1,409,800,000.00 | 1,603,500,000.00 | 1,861,400,000.00 | 2,044,200,000.00 | 2,213,600,000.00 | 2,517,000,000.00 |
| Total equity | 6.69B | 8.28B | 9.76B | 11.95B | 11.11B | 13.40B | 16.53B | 17.94B |
| Retained earnings | 1.52B | 2.49B | 3.26B | 4.76B | 3.50B | 4.74B | 6.80B | 7.01B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 7.66B | 8.75B | 8.53B | 9.78B | 8.81B | 9.54B |
| Cash & ST investments | 4.51B | 5.33B | 4.91B | 5.93B | 4.52B | 5.22B |
| Inventory | 1.55B | 1.67B | 1.78B | 1.84B | 1.95B | 2.03B |
| Total assets | 19.22B | 20.16B | 19.35B | 20.46B | 20.11B | 20.88B |
| Total current liabilities | 1.54B | 1.69B | 1.80B | 2.01B | 1.91B | 1.92B |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 2,012,700,000.00 | 2,210,100,000.00 | 2,309,700,000.00 | 2,517,000,000.00 | 2,513,800,000.00 | 2,578,900,000.00 |
| Total equity | 17.21B | 17.95B | 17.04B | 17.94B | 17.60B | 18.30B |
| Retained earnings | 7.14B | 7.61B | 6.42B | 7.01B | 6.40B | 6.84B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.17B | 1.60B | 1.48B | 2.09B | 1.49B | 1.81B | 2.42B | 3.03B |
| Depreciation & amortization | 122.80M | 203.00M | 276.20M | 310.20M | 365.80M | 454.80M | 499.70M | 677.10M |
| Free cash flow | 982.20M | 1.17B | 1.14B | 1.75B | 958.40M | 749.60M | 1.30B | 2.49B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -269.50M | -134.30M | 0 | -2.61B | -416.30M | 0 | -2.30B |
| Ending cash balance | 909.40M | 1.18B | 1.64B | 1.31B | 1.60B | 2.77B | 2.06B | 3.41B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 581.60M | 715.40M | 841.00M | 892.50M | 911.90M | 1.06B |
| Depreciation & amortization | 149.60M | 164.40M | 142.20M | 220.90M | 200.00M | 231.10M |
| Free cash flow | 465.00M | 560.10M | 735.60M | 730.00M | 808.60M | 948.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -181.00M | -1.91B | -201.00M | -1.12B | -320.30M |
| Ending cash balance | 2.62B | 3.45B | 2.85B | 3.41B | 2.05B | 2.81B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.78 | 18.46 | 11.79 | 15.76 | 11.53 | 14.77 | 15.62 | 16.67 |
| ROA %i | 16.58 | 15.69 | 10.15 | 13.79 | 9.97 | 12.66 | 13.59 | 14.57 |
| ROIC %i | 18.55 | 16.89 | 10.24 | 15.05 | 11.31 | 13.30 | 13.71 | 14.82 |
| 5-year avg ROE %i | 14.90 | 16.16 | 15.45 | 15.68 | 15.44 | 14.46 | 13.89 | 14.87 |
| EBIT margin %i | 32.21 | 30.69 | 24.09 | 31.89 | 25.35 | 24.80 | 28.12 | 29.27 |
| FCF / sales %i | 26.37 | 26.18 | 26.23 | 30.40 | 15.40 | 10.52 | 15.61 | 24.75 |
| Current ratioi | 5.28 | 4.53 | 6.86 | 5.08 | 4.40 | 4.76 | 4.07 | 4.87 |
| Quick ratioi | 4.56 | 3.81 | 6.11 | 4.46 | 3.65 | 3.91 | 3.08 | 3.77 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 16.02 | 18.28 | 11.57 | 15.31 | 11.58 | 17.80 | 13.51 | 17.39 |
| Net income CAGR (3Y) %i | 24.19 | 23.16 | 16.49 | 14.76 | -1.40 | 19.24 | 10.86 | 29.26 |
| FCF CAGR (3Y) %i | 10.64 | 4.31 | 6.25 | 21.23 | -6.50 | -13.13 | -9.34 | 37.49 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 15.94 | 16.02 | 16.90 | 16.67 | 17.23 | 17.43 |
| ROA %i | 14.13 | 14.17 | 14.81 | 14.57 | 15.15 | 15.30 |
| ROIC %i | 13.96 | 14.14 | 15.02 | 14.82 | 15.48 | 15.80 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 28.20 | 28.80 | 29.30 | 29.27 | 30.45 | 31.28 |
| FCF / sales %i | 20.03 | 21.81 | 23.63 | 24.75 | 26.78 | 29.21 |
| Current ratioi | 4.98 | 5.17 | 4.73 | 4.87 | 4.61 | 4.96 |
| Quick ratioi | 3.81 | 3.97 | 3.49 | 3.77 | 3.26 | 3.64 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Instruments and accessories is the largest reported line at 59.98% of revenue, across 3 reported segments.
- Systems follows at 23.68%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Instruments and accessories59.98%
Systems23.68%
Service16.33%
Quote time 2026-10-08 08:25:09 · For reference only, not investment advice and not tailored to your situation.